EP4147689A1 — Lenvatinib formulation
Assigned to Lotus Pharmaceutical Co Ltd · Expires 2023-03-15 · 3y expired
What this patent protects
The present invention provides a pharmaceutical formulation comprising Lenvatinib or a pharmaceutically acceptable salt thereof and at least one alkalizer, and optionally at least one disintegrant. The formulation is stable and has a beneficial dissolution profile.
USPTO Abstract
The present invention provides a pharmaceutical formulation comprising Lenvatinib or a pharmaceutically acceptable salt thereof and at least one alkalizer, and optionally at least one disintegrant. The formulation is stable and has a beneficial dissolution profile.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.